Larimar Therapeutics, Inc.
LRMR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $237,061 | $199,751 | $106,395 | $185,203 |
| - Cash | $33,218 | $26,749 | $26,825 | $70,097 |
| + Debt | $5,117 | $5,546 | $5,408 | $6,002 |
| Enterprise Value | $208,960 | $178,548 | $84,978 | $121,108 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$90,572 | -$41,447 | -$36,208 | -$50,139 |
| % Margin | – | – | – | – |
| Net Income | -$80,604 | -$36,949 | -$35,355 | -$50,636 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.32 | -0.84 | -1.33 | -2.93 |
| % Growth | -57.1% | 36.8% | 54.6% | – |
| Operating Cash Flow | -$70,760 | -$33,459 | -$27,569 | -$42,105 |
| Capital Expenditures | -$515 | -$164 | -$100 | -$333 |
| Free Cash Flow | -$71,275 | -$33,623 | -$27,669 | -$42,438 |